Navigation Links
Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
Date:6/6/2009

treatment and were maintained over one year.

Results from the three other Phase 3 trials (NB-301, NB-303, NB-304) are expected to be announced in the third quarter of 2009. Pending positive results, the Company is on track to submit a New Drug Application (NDA) with the FDA in the first half of 2010.

About NB-302

NB-302 was a 56-week, double-blind, placebo-controlled trial, conducted in 793 patients at nine U.S. centers. The trial evaluated the additional weight loss of Contrave (32mg naltrexone SR/360mg bupropion SR) when added to an intensive behavior modification program consisting of counseling, diet and exercise. The co-primary endpoints were percent change in total body weight from baseline and proportion of patients who lost at least 5% of their baseline body weight.

Based on pre-specified intent-to-treat and completer analyses, obese patients treated with Contrave lost an average of 20.3 pounds to 25.0 pounds, or 9.3% to 11.5% of their baseline body weight, versus 11.0 pounds to 16.0 pounds, or 5.1% to 7.3% of baseline body weight, for patients treated with placebo. In addition, in the categorical weight reduction analysis, the percentage of patients who lost greater than or equal to 10% of their body weight was 41.5% in the Contrave group, compared to 20.2% in the placebo group. Furthermore, 29.1% of patients lost greater than or equal to 15% of their body weight in the Contrave group; compared to 10.9% in the placebo group. All of these findings were highly statistically significant (p< 0.001).

"NB-302 demonstrates that Contrave delivers greater weight loss to patients when added to a rigorous behavioral intervention program compared to the intervention program alone, underscoring the important role of pharmacotherapy as part of a weight management program," said Michael Narachi, President and Chief Executive Officer, Orexigen Therapeutics. "These data
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
2. Orexigen(R) Therapeutics to Present at Upcoming Meetings
3. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
4. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
5. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
6. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
7. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
8. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
9. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
10. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
11. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 5, 2015 Psyche Systems Corporation and Luminate ... a first-of-its-kind platform that helps labs comply with new ... transforms the way patients engage with these results, and ... provides a HIPAA-compliant digital platform that gives labs ... understand their lab results, and uniquely connects labs, physicians, ...
(Date:5/5/2015)... , May 5, 2015  Renova™ Therapeutics, a ... heart failure and other chronic diseases, has engaged ... analysis designed to reflect the healthcare patterns of ... model will be used to characterize the impact ... have on those groups of patients and the ...
(Date:5/5/2015)... 2015  A group of biotechnology executives and medical ... Institute, a non-profit organization dedicated to providing education, research ... disorders of consciousness.  ... Coma ... no voluntary actions can be initiated by the patient, ...
(Date:5/5/2015)... May 05, 2015 Research and Markets ... of the "Clinical Laboratory, Molecular Diagnostics and ... to 2019 - Global Version" report to ... in the area of molecular diagnostics and pharmacogenics ... evolving world market that is moving out of ...
Breaking Biology Technology:Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 2Psyche Systems Corporation Forms Strategic Alliance with Luminate Health to Provide First-of-its-kind Patient Access Solution 3RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... YORK, August 28 XTL Biopharmaceuticals,Ltd. (NASDAQ: ... company,engaged in the acquisition, development and commercialization of,therapeutics ... pain and hepatitis C, today announced that issuances ... depositary bank,The Bank of New York, will be ...
... IVD Revenue Exceeded HIFU Revenue ... FY2007 Annual Targets Under ... Inc. (the "Company") (Nasdaq: CMED ), a leading ... in-,vitro diagnostic products and high intensity focused ultrasound tumor,therapy ...
... ARUP Laboratories, a national,clinical and anatomic pathology ... and development, announced today that it has,renewed a ... one of the nation,s largest purchasing alliances of ... a previous,contract between ARUP and Premier which has ...
Cached Biology Technology:Processing Fees on ADRs to be Waived for two Months 2Processing Fees on ADRs to be Waived for two Months 3China Medical Technologies Reports First Quarter Financial Results 2China Medical Technologies Reports First Quarter Financial Results 3China Medical Technologies Reports First Quarter Financial Results 4China Medical Technologies Reports First Quarter Financial Results 5China Medical Technologies Reports First Quarter Financial Results 6China Medical Technologies Reports First Quarter Financial Results 7China Medical Technologies Reports First Quarter Financial Results 8China Medical Technologies Reports First Quarter Financial Results 9China Medical Technologies Reports First Quarter Financial Results 10China Medical Technologies Reports First Quarter Financial Results 11China Medical Technologies Reports First Quarter Financial Results 12China Medical Technologies Reports First Quarter Financial Results 13China Medical Technologies Reports First Quarter Financial Results 14ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services 2
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... useful new tool for creating chemical reactions between ... Standards and Technology (NIST) have employed microfluidicsthe manipulation ... that contain single molecules of interest. By combining ... that could merge multiple droplets and cause their ...
... at the National Institute of Standards and Technology (NIST) ... therapy has uncovered a delicate balancing act that makes ... should be. Just like individuals in a crowd respecting ... get close together, but not too close. In ...
... are a girl,s best friend. But a research team including ... (NIST) has recently found* that the gems might turn out ... team,s work has the long-term goal of developing quantum computers, ... application in medical science. Their finding that a candidate "quantum ...
Cached Biology News:New nanochemistry technique encases single molecules in microdroplets 2Therapeutic nanoparticles give new meaning to sugar-coating medicine 2Diamonds may be the ultimate MRI probe, say Quantum physicists 2
Useful for determination of glucose and ATP. Packaging: Package sizes are based on hexokinase units. Preparation Unit Definition: One unit will phosphorylate 1.0 mol of D -glucose per min at pH ...
... Physical form: Lyophilized powder ... Preparation Unit Definition: One ... of 2-phosphoglycerate to phospho(enol)pyruvate ... at 25 C. Chem ...
SCCRO (S-17)...
Packaging: 6 bottles for 1 l ready-to-use-solution ID clarifier: ready-to-use solution ...
Biology Products: